netazepide
netazepide is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Registry-listed formulations
netazepide · chembl:CHEMBL324547
Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.
5 source entries across 5 studies. This list may not include all unresolved or historical entries.
- YF476Registry intervention
Linked study entry; product equivalence not established
View study and source - YF476Registry intervention
Linked study entry; product equivalence not established
View study and source - YF476Registry intervention
Linked study entry; product equivalence not established
View study and source - YF476Registry intervention
Linked study entry; product equivalence not established
View study and source - YF476Registry intervention
Linked study entry; product equivalence not established
View study and source
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
5
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
66.7%
4 of 6 finished
33.3%
2 ended early
0
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus
YF476 in Barrett's Esophagus
YF476 and Type II Gastric Carcinoids
YF476 and Type I Gastric Carcinoids
Effect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin
Clinical Trials (6)
Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus
YF476 in Barrett's Esophagus
YF476 and Type II Gastric Carcinoids
YF476 and Type I Gastric Carcinoids
Effect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin
YF476 and Type I Gastric Carcinoids (Norway)
All 6 trials loaded
Drug Details
- Intervention Type
- Drug
- Molecule Type
- Protein
- Total Trials
- 6